Volume 7 Supplement 1
GW501516, a PPAR-BETA/DELTA agonist, improves inflammatory pathways in the kidney of high-fructose fed mice
© Magliano et al. 2015
Published: 11 November 2015
Angiotensin-II type 1 receptor (AT1r) high activation is closely linked to a low-grade inflammation and oxidative stress that yield impaired renal function and, consequently, chronic kidney disease (CKD).
Therefore, the aim of this study was to verify if GW501516 could improve damage in the kidney of mice with high activation of AT1r.
Materials and methods
To induce high activation of this receptor, mice were fed a high-fructose diet for eight weeks. The control group only received standard-chow (SC). After, the animals were randomly divided into four groups and the administration of GW501516 started and lasted three weeks. Morphological variables and urinary and plasmatic determinations were assessed. Renin and angiotensin converting enzyme (ACE)/AT1r axis protein and gene expression were evaluated as well as inflammatory cytokines and proteins. Also, the protein and gene expression of the antioxidant enzymes were verified.
GW501516 activated PPAR-beta/delta and its target genes PDK4 and CPT-1. Despite showing no effects either on ACE/AT1r axis or renin expression, GW501516 improved the inflammatory state in the kidney. It elicits an expressive reduction in the expression of inflammatory genes such as IL-1β, IL-6, MCP-1 and Cd68, irrespective of AT1 downregulation. However, no differences were found in oxidative stress.
We conclude that GW501516, a PPAR-beta/delta agonist, acts downstream AT1r activation, improving inflammatory pathways in the kidney of high-fructose fed model.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.